Nearly 15% of older men with hypogonadism experience anemia. TRAVERSE is the first trial to report the effects of testosterone replacement therapy (TRT) on anemia incidence in hypogonal men.
Nearly 15% of older men with hypogonadism experience anemia. TRAVERSE is the first trial to report the effects of testosterone replacement therapy (TRT) on anemia incidence in hypogonal men.
CHICAGO — Older men with hypogonadism and high risk for cardiovascular disease who received testosterone therapy had similar rates of CV events as those who received placebo, according to findings from the TRAVERSE trial.
In data presented at ENDO 2023 and simultaneously published in The New England Journal of Medicine, the use of testosterone therapy among men aged 45 to 80 years with